BioSyent Inc.

2601 Matheson Boulevard E.
Suite 5
Mississauga
Ontario
L4W 5A8
Canada

Tel: 905-206-0013
Fax: 905-206-1413

Show jobs for this employer

59 articles with BioSyent Inc.

  • BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming Bloom Burton & Co. Healthcare Investor Conference

  • BioSyent Inc. announces that its Board of Directors has approved a grant of 67,252 Restricted Share Units “RSUs” to certain directors, officers, management, and employees of the Company pursuant to the Company’s Restricted Share Unit Plan.

  • BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and twelve months ended December 31, 2020.

  • BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended December 31, 2020 on Wednesday, March 17, 2021.

  • BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has commenced the first shipments of Combogesic ® to Canadian wholesalers. Combogesic ® is the first fixed-dose combination of acetaminophen and ibuprofen in a single tablet in Canada and is indicated for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Combining two

  • MISSISSAUGA, Ontario, Dec. 11, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the Company’s Notice of Intention to Make a Normal Course Issuer Bid (the “NCIB”). Pursuant to the NCIB, BioSyent may purchase up to 950,000 of its common shares (“Shares”) over a 12-month period, representing approximately 7.42% of the Shares outstanding as of December 11, 2020.   The NCIB will commence

  • BioSyent Inc. released its financial results for the three and nine months ended September 30, 2020.

  • BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended September 30, 2020 on Thursday, November 26, 2020. A presentation on the Company’s third quarter and year-to-date 2020 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exchange und

  • BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce the launch of FeraMAX® Pd Therapeutic 150, the first new product incorporating FeraMAX® Pd, a new oral iron supplement delivery system, by its subsidiary BioSyent Pharma Inc. in Canada.

  • BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it has been included in the 32nd annual Growth List, the definitive ranking of Canada’s Fastest-Growing Companies by Canadian Business and Maclean’s.

  • BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce the introduction of FeraMAX ® Pd, a new oral iron supplement formulation, by its subsidiary BioSyent Pharma Inc. FeraMAX ® Pd is a patented delivery system for the treatment of iron deficiency anemia and will be the foundation of future product developments. BioSyent Pharma has a deep expertise and experience in the iron deficiency anemia therapy and pre

  • BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has signed an exclusive License and Supply Agreement with a European partner for a new product in the women’s health market for Canada. The product has been approved for sale in Canada, the U.S.A., Europe and in several other markets around the world.   BioSyent intends to launch the product to the Canadian market in Q2 2021. “We

  • BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three and six months ended June 30, 2020. Key highlights include:  Second quarter (Q2) 2020 Net Revenues of $4,771,255 decreased by 7% versus Q2 2019 First half (H1) 2020 Net Revenues of $10,834,101 increased by 12% versus H1 2019 Q2 2020 Canadian Pharmaceutical Net Revenues of $4,415,900 decreased by 9% versus Q2 2019 H1 2020 Canadi

  • BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) today announced that it will be presenting at the LD 500 investor conference on Thursday, September 3rd at 2:40 p.m. (ET). 

  • BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and six months ended June 30, 2020 on Wednesday, August 26, 2020. 

  • BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) today announced the Canadian launch and product availability of Tibella® (tibolone) for short-term treatment of vasomotor symptoms due to estrogen deficiency in postmenopausal women, more than one year after menopause. 

  • BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three months ended March 31, 2020. Key highlights include: First quarter (Q1) 2020 Net Revenues of $6,062,846 increased by 35% versus Q1 2019 Q1 2020 Canadian Pharmaceutical Net Revenues of $5,955,561 increased by 39% versus Q1 2019 Q1 2020 EBITDA 1 of $1,997,987 increased by 66% versus Q1 2019 Q1 2020 Net Income After Taxes (NIAT)

  • BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2020 on Thursday, May 28, 2020.  A presentation on the Company’s first quarter 2020 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release.   About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSye

  • BioSyent Inc. announces that its Board of Directors has approved a grant of 129,125 Restricted Share Units “RSUs” to certain directors, officers, management, and employees of the Company pursuant to the Company’s Restricted Share Unit Plan.

  • BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three and twelve months ended December 31, 2019.  Key highlights include: Fourth quarter (Q4) 2019 Net Revenues of $5,569,286 decreased by 6% versus Q4 2018 Full year (FY) 2019 Net Revenues of $21,424,324 flat versus FY 2018 Q4 2019 Canadian Pharmaceutical Net Revenues of $5,042,899 flat versus Q4 2018 FY 2019 Canadian Pharmaceutic